Luc Meuleners

714 total citations
22 papers, 562 citations indexed

About

Luc Meuleners is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, Luc Meuleners has authored 22 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Rheumatology and 11 papers in Hematology. Recurrent topics in Luc Meuleners's work include Chronic Lymphocytic Leukemia Research (12 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Luc Meuleners is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Luc Meuleners collaborates with scholars based in Belgium, United States and United Kingdom. Luc Meuleners's co-authors include Chantal Tasset, R. Besuyen, Annegret Van der Aa, Joy M. Greer, Neelufar Mozaffarian, Walid Abi‐Saab, Mykola Stanislavchuk, Pille Harrison, Thijs Hendrikx and Ke Liu and has published in prestigious journals such as The Lancet, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

Luc Meuleners

22 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luc Meuleners Belgium 7 414 239 221 152 92 22 562
Horny Hp Germany 12 224 0.5× 316 1.3× 88 0.4× 41 0.3× 67 0.7× 23 434
Dao X. Nguyen United Kingdom 9 121 0.3× 236 1.0× 64 0.3× 70 0.5× 26 0.3× 9 410
G Meloni Italy 11 118 0.3× 63 0.3× 461 2.1× 80 0.5× 268 2.9× 24 547
Niklas Hagberg Sweden 14 285 0.7× 407 1.7× 26 0.1× 93 0.6× 17 0.2× 21 533
C Bilhou-Nabéra France 12 149 0.4× 39 0.2× 345 1.6× 65 0.4× 240 2.6× 25 452
Maria J H Boumans Netherlands 8 167 0.4× 127 0.5× 32 0.1× 52 0.3× 48 0.5× 10 339
Belinda Baltus Netherlands 9 158 0.4× 185 0.8× 44 0.2× 113 0.7× 17 0.2× 11 409
A. E. Irvine United Kingdom 8 116 0.3× 202 0.8× 83 0.4× 82 0.5× 29 0.3× 9 417
Naoko Yoshio‐Hoshino Japan 8 147 0.4× 154 0.6× 113 0.5× 114 0.8× 27 0.3× 9 432
Laura Wisch United States 6 38 0.1× 214 0.9× 133 0.6× 69 0.5× 24 0.3× 10 336

Countries citing papers authored by Luc Meuleners

Since Specialization
Citations

This map shows the geographic impact of Luc Meuleners's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Meuleners with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Meuleners more than expected).

Fields of papers citing papers by Luc Meuleners

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Meuleners. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Meuleners. The network helps show where Luc Meuleners may publish in the future.

Co-authorship network of co-authors of Luc Meuleners

This figure shows the co-authorship network connecting the top 25 collaborators of Luc Meuleners. A scholar is included among the top collaborators of Luc Meuleners based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luc Meuleners. Luc Meuleners is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kavanaugh, Arthur, René Westhovens, Kevin Winthrop, et al.. (2021). Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. The Journal of Rheumatology. 48(8). 1230–1238. 37 indexed citations
2.
Desrivot, Julie, Sonia Dupont, Luc Meuleners, et al.. (2021). GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(9). 994–1006. 5 indexed citations
3.
Husni, M. Elaine, Dafna D. Gladman, Philip Helliwell, et al.. (2020). FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. Annals of the Rheumatic Diseases. 79. 766–766. 2 indexed citations
4.
Gladman, Dafna D., Laura C. Coates, Filip Van den Bosch, et al.. (2020). FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). Annals of the Rheumatic Diseases. 79. 763–763. 2 indexed citations
5.
Helliwell, Philip, Filip Van den Bosch, Laura C. Coates, et al.. (2020). FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). Annals of the Rheumatic Diseases. 79. 765–766. 3 indexed citations
6.
Besuyen, R., Arthur Kavanaugh, René Westhovens, et al.. (2020). P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study. Journal of Crohn s and Colitis. 14(Supplement_1). S452–S452. 3 indexed citations
7.
Orbai, Ana‐Maria, Alexis Ogdie, Laure Gossec, et al.. (2019). Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Lara D. Veeken. 59(7). 1495–1504. 22 indexed citations
8.
Coates, Laura C., Philip J. Mease, Dafna D. Gladman, et al.. (2019). SAT0373 EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. Annals of the Rheumatic Diseases. 78. 1269–1270. 2 indexed citations
9.
Mease, Philip J., Dafna D. Gladman, Filip Van den Bosch, et al.. (2019). OP0109 EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. Annals of the Rheumatic Diseases. 78. 128–128. 1 indexed citations
10.
Genovese, Mark C., René Westhovens, Luc Meuleners, et al.. (2018). Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Research & Therapy. 20(1). 57–57. 44 indexed citations
11.
Heijde, Désirée van der, Xenofon Baraliakos, Lianne S. Gensler, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2378–2387. 194 indexed citations
12.
Mease, Philip J., Laura C. Coates, Philip Helliwell, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2367–2377. 156 indexed citations
13.
D’Haens, Geert, Stefan Schreiber, Tanja Kuehbacher, et al.. (2017). DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease. Journal of Crohn s and Colitis. 11(suppl_1). S70–S71. 1 indexed citations
14.
Alten, Rieke, René Westhovens, Arthur Kavanaugh, et al.. (2017). THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. Annals of the Rheumatic Diseases. 76. 267–267. 3 indexed citations
15.
Vanhoutte, Frédéric, Minodora Mazur, Mykola Stanislavchuk, et al.. (2017). Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis & Rheumatology. 69(10). 1949–1959. 61 indexed citations
16.
Vermeire, Séverine, Stefanie Schreiber, Tanja Kuehbacher, et al.. (2017). OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study. Journal of Crohn s and Colitis. 11(suppl_1). S13–S14. 4 indexed citations
17.
18.
Genovese, Mark C., René Westhovens, Arthur Kavanaugh, et al.. (2016). THU0167 The Effect of Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2b Dose Ranging Studies. Annals of the Rheumatic Diseases. 75. 244–244. 4 indexed citations
19.
Vanhoutte, Frédéric, Annegret Van der Aa, Luc Meuleners, & Gerben van ‘t Klooster. (2013). THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial. Annals of the Rheumatic Diseases. 72. A242–A242. 1 indexed citations
20.
Singh, Dave, Zöe Borrill, Gianluigi Poli, et al.. (2008). Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulmonary Pharmacology & Therapeutics. 21(3). 551–557. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Horny Hp Breakdown of academic impact, for papers by Dao X. Nguyen Breakdown of academic impact, for papers by G Meloni Breakdown of academic impact, for papers by Niklas Hagberg Breakdown of academic impact, for papers by C Bilhou-Nabéra Breakdown of academic impact, for papers by Maria J H Boumans Breakdown of academic impact, for papers by Belinda Baltus Breakdown of academic impact, for papers by A. E. Irvine Breakdown of academic impact, for papers by Naoko Yoshio‐Hoshino Breakdown of academic impact, for papers by Laura Wisch
Rankless by CCL
2026